Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00059878 · ClinicalTrials.gov registry record · Phase 2
Voriconazole With or Without Interferon Gamma in Treating Patients With Aspergillosis or Other Fungal Infections
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00059878: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00059878 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00059878, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Antifungals such as voriconazole may be effective in controlling fungal infections. Combining voriconazole with interferon gamma may be more effective than voriconazole alone in treating fungal infections. PURPOSE: Randomized phase II trial to compare the effectiveness of voriconazole with or without interferon gamma in treating patients who have aspergillosis or other fungal infections.
Interventions
- BIOLOGICAL recombinant interferon gamma
- DRUG voriconazole
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-08 |
| Est. Completion | 2005-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00059878
The ClinicalTrials.gov registry entry for NCT00059878 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which recombinant interferon gamma is the first listed.
NCT00059878 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00059878 about?
NCT00059878 is a clinical study titled "Voriconazole With or Without Interferon Gamma in Treating Patients With Aspergillosis or Other Fungal Infections". RATIONALE: Antifungals such as voriconazole may be effective in controlling fungal infections. Combining voriconazole with interferon gamma may be more effective than voriconazole alone in treating fungal infections. PURPOSE: Randomized phase II trial to compare the effectiveness of voriconazole wi...
What is the current status of trial NCT00059878?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-08. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00059878?
The interventions under investigation include: recombinant interferon gamma (BIOLOGICAL), voriconazole (DRUG).
Who is sponsoring clinical trial NCT00059878?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.